E
Elf Life Sciences
Recombinant gene technology and vaccine development
About Elf Life Sciences
Shanghai United Cell Biotechnology Co., Ltd. (SUCB), founded in 1995 by Unilab Inc., is a high-tech enterprise focused on the research, development, production, and sales of genetically engineered vaccines and therapeutic biological products. Currently affiliated with Brilliance Group and backed by major investor Hillhouse Capital, the company operates from the Jinqiao Biotechnology Industrial Park within the Shanghai Pilot Free Trade Zone.
SUCB specializes in recombinant gene technology to create biopharmaceutical and vaccine products. Its product portfolio includes Recombinant Parathyroid Hormone for Injection, Recombinant Human Growth Hormone for Injection, and a Recombinant B-subunit/Whole cell cholera vaccine. The company's business model encompasses the entire lifecycle from R&D to manufacturing and marketing, serving the biopharmaceutical market. Its production facility has the capacity for millions of units of freeze-dried powder injections, cartridge injections, capsules, and granule preparations annually. To expand its operations, SUCB established Zhuhai United Cell Biotechnology Co., Ltd. in 2015.
The company has consistently focused on innovation and quality management, aiming to meet international standards. In 2022, SUCB was recognized as a “Specialized, special and new enterprise” in Shanghai.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Vaccines, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Aug 2025 | $14M | $55M | Wuhan Optics Valley Industrial Investment · Legend Capital · Mingxi Capital | ↗ |
Growth signals
Latest recorded traffic for Elf Life Sciences is 370 monthly website visits, up 184.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- WIWuhan Optics Valley Industrial Investment
Legend Capital- MCMingxi Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elf Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elf Life Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.